Identification of novel small-molecule inhibitors of α-methylacyl-CoA (AMACR; P504S) and structure-activity relationships by Petrova, Yoana D. et al.
  
 
 
 
Identification of novel small-molecule inhibitors of α-methylacyl-CoA 
racemase (AMACR; P504S) and structure-activity relationships 
 
 
 
 
T  
 
Yoana D. Petrova
a
, Katty Wadda
a,b
, Amit Nathubhai
a,c
, Maksims Yevglevskis
a
, Paul J. Mitchell
a
, 
Tony D. James
b
, Michael D. Threadgill
a
, Timothy J. Woodman
a
, Matthew D. Lloyd
a, 
a Drug & Target Discovery, Department of Pharmacy & Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK 
b Department of Chemistry, University of Bath, Claverton Down, Bath BA2 7AY, UK 
c School of Pharmacy and Pharmaceutical Sciences, Sciences Complex, City Campus, Dale Building, Room 121, Sunderland SR1 3SD, UK1  
 
 
ARTICLE INFO  
 
Keywords:  
Branched-chain fatty acids  
Mixed competitive inhibition  
High-throughput screening  
Ibuprofen metabolism  
α-Methylacyl-CoA racemase (AMACR P504S)  
Prostate cancer  
Structure-activity relationships  
Uncompetitive inhibition 
 
 
ABSTRACT  
 
α-Methylacyl-CoA racemase (AMACR; P504S; EC 5.1.99.4) catalyses epimerization of 2-methylacyl-CoAs and is 
important for the degradation of branched-chain fatty acids and the pharmacological activation of ibuprofen and 
related drugs. It is also a novel drug target for prostate and other cancers. However, development of AMACR as a 
drug target has been hampered by the difficulties in assaying enzyme activity. Consequently, reported inhibitors 
have been rationally designed acyl-CoA esters, which are delivered as their carboxylate prodrugs. The novel 
colorimetric assay for AMACR based on the elimination of 2,4-dinitrophenolate was developed for high-throughput 
screening and 20,387 ‘drug-like compounds’ were screened, with a throughput of 768 compounds assayed per 
day. Pyrazoloquinolines and pyrazolopyrimidines were identified as novel scaffolds and investigated as AMACR 
inhibitors. The most potent inhibitors have IC50 values of ~2 µM. The pyrazoloquinoline inhibitor 10a displayed 
uncompetitive inhibition, whilst 10j displayed mixed competitive inhibition. The pyrazolopyr-imidine inhibitor 11k 
displayed uncompetitive inhibition. This is the first report of the identification of specific drug-like small-molecule 
AMACR inhibitors by high-throughput screening. Pyrazoloquinolines and pyr-azolopyrimidines may also be useful 
as inhibitors of other CoA-utilizing enzymes.  
 
 
1. Introduction 
 
Branched-chain fatty acids are common in the diet and derivatives 
thereof are used as medicines. 2-Methyl-fatty acids are derived cata-
bolically from dietary 3-methyl-fatty acid precursors (e.g. phytanic acid) 
or are made endogenously (e.g. the bile acids derived from cho-
lesterol) [1–4]. The β-oxidation pathway, which degrades 2-methyl fatty 
acids, can only process S-2-methylacyl-CoAs [5–7] but a mixture of R- 
and S-2-methylacyl-CoAs are produced from phytanic acid [3], whilst 
bile acids are predominantly produced as R-2-methylacyl-CoAs [1,8]. 
The enzyme α-methylacyl-CoA racemase (AMACR; P504S; EC 
5.1.99.4) catalyses conversion of R-2-methylacyl-CoAs to a near 1:1 
epimeric mixture of 2-methylacyl-CoAs [9,10] by a deprotonation/re-
protonation reaction [9–12], probably via an enolate intermediate 
[13,14]. The resulting S-2-methylacyl-CoAs undergo β-oxidation, whilst 
the remaining R-2-methylacyl-CoAs are further converted to their 2S 
 
 
 
epimers by AMACR, allowing their complete degradation [1–4]. 
AMACR is also involved in the pharmacological activation of ibuprofen 
and similar drugs [1,2,10].  
AMACR protein levels are increased in prostate cancer [15,16], 
breast cancer [17], myxofibrosarcomas [18], some colon cancers [19] 
and various other cancers [1,20]. Increased catalytic activity has also 
been reported in prostate cancers [16,21]. Reducing protein levels of 
active spliced variants in prostate cancer cell lines results in reduced 
proliferation [21,22], which is synergistic with deprivation of andro-gens 
[21]. Some advanced prostate cancer cell lines revert from an-drogen-
independent to androgen-dependent growth upon knock-down of 
AMACR [23]. Intriguingly, long-term use of low dose ibuprofen ap-
pears to reduce the risk of prostate [24] and colon cancer [25] in pa-
tients with particular AMACR single-nucleotide polymorphisms (SNPs). 
Consequently, there has been considerable interest in AMACR as both 
a drug target and cancer marker. 
 
Abbreviations: AMACR, α-methylacyl-CoA racemase (P504S); DMSO, dimethylsulfoxide; FAR, fatty acyl-CoA racemase from Mycobacterium tuberculosis; MCR, 2-
methylacyl-CoA racemase from Mycobacterium tuberculosis; S.E.M., standard error of the mean 
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Fig. 1. Examples of previously reported rationally designed AMACR inhibitors 1–
4 [29–32] and inhibitors 5 and 6 of MCR [33,34], the M. tuberculosis homologue 
of AMACR. 
 
Development of AMACR as a drug target has been difficult because of 
the lack of an X-ray crystal structure of the human enzyme (although 
structures of the M. tuberculosis homologues, MCR [11–13] and FAR [26], 
have been reported), and because of the difficulties of assaying the 
enzyme [27,28]. Therefore, the majority of studies have focused on rational 
drug design strategies to produce inhibitors of AMACR (ex-amples shown 
in Fig. 1, 1–4) [29–32] or its bacterial homologue, MCR (examples shown in 
Fig. 1, 5 and 6) [33,34]. These studies have pro-duced highly potent acyl-
CoA inhibitors [29–32] but these do not comply with Lipinski’s guidelines 
[35,36] and must be delivered to cells as their carboxylic acid precursors. 
Only one study has investigated the use of a screening approach to identify 
inhibitors [22]. The authors of this study successfully screened a library of 
~5000 compounds, and identified a number of non-specific protein 
modification agents as in-hibitors of AMACR [2,22]. However, the assay 
was discontinuous, used a labelled substrate with measured rates subject 
to a kinetic isotope effect, and was labour-intensive. Consequently, this 
assay is not well-suited for screening large libraries of drug-like 
compounds. 
 
We recently reported the development of a novel continuous col-
orimetric assay for the measurement of AMACR activity [28]. This 
assay is based on the use of a colourless substrate 7, which 
eliminates 2,4-dinitrophenolate 8 (which is intensely yellow) and forms 
un-saturated product 9 (Scheme 1). This assay was previously used to 
examine structure-activity relationships of known inhibitors and other 
acyl-CoAs known to bind to AMACR [28,37]. Herein, we report a study 
in which this assay was used to screen libraries containing 20,387 
drug-like’ molecules, identify novel AMACR inhibitors and examine 
struc-ture-activity relationships. 
 
2. Results and discussion 
 
2.1. Screening strategy for inhibitors 
 
The colorimetric assay was selected for development for high-
throughput screening applications, owing to its irreversible conversion 
of substrate to products and the ability to follow continuously the for-
mation of 2,4-dinitrophenolate 8 at 354 nm. A substrate concentration 
of 40 µM was chosen, as this is close to the reported Km value for 
substrate 7 [28,37]. These ‘balanced conditions’ result in equal pro-
portions of free enzyme and enzyme-substrate complex and facilitates 
identification of inhibitors with diverse kinetic mechanisms [38]. There  
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Scheme 1. Elimination of colorimetric substrate 7 by AMACR to give yellow 2,4-
dinitrophenolate 8 and unsaturated product 9. 
 
 
was considerable variation in the background absorbance at 354 nm 
between different microtitre plate wells and hence formation of product was 
followed using a time course, typically of 8 min. This also improved the 
ease of analysing compounds which had significant absorbance at 354 nm. 
Under the standard assay conditions (see Experimental for details), a 
robustness (Z′ factor [39]) of 0.71 ± 0.13 was calculated. This compares 
with previously reported value of 0.906 [28]. The sta-tistical parameters for 
the assay (Supporting Information, Table S1) show that it is suitable for the 
identification of AMACR inhibitors.  
Two libraries of compounds were obtained from LifeArc (formerly 
MRC technology). A library containing 10,419 molecules designed to 
interact with the hinge-region ATP-binding pocket of kinases was 
chosen. As ATP and CoA share a common nucleotide structure, it was 
thought that ‘kinase-like’ inhibitors would compete with the adenosine 
moiety of the acyl-CoA substrate. The second library of compounds 
was the index set, containing a clustered collection of 9968 drug-like 
mo-lecules [40]. Compounds were supplied as 1.0 mM stock solutions 
in DMSO and were used at a final concentration of 30 µM in the assay 
[also giving a final concentration 3.0% (v/v) DMSO in each well]. 
Potential inhibitors were incubated with enzyme for 10 min before 
addition of substrate, in order to allow time for the enzyme-inhibitor 
complex to form. Potential hits were re-assayed to confirm the dimin-
uation in enzyme activity and were compared with positive (en-zyme + 
DMSO) and negative (buffer + DMSO) controls. Use of two 96-well 
plates in tandem with an 8-min time course allowed screening of 768 
library wells (2 × 384 plates of inhibitor) per day and this could be 
increased to 1152 library wells (three plates) per day. Using this pro-
tocol, 89 hits (~0.4%) were initially identified for further investigation. 
The compounds identified were triaged based on Lipinski guidelines 
(LogP = < 5, MW = < 500 [35,36] and ‘frequent hitter’ status [41,42]. 
From this analysis, pyrazoloquinolines 10a-10q (Table 1) and 
 
Table 1  
IC50 values for the series of pyrazoloquinoline inhibitors 10 as measured by the 
colorimetric assay [28] and calculated lipophilicity. IC50 values are expressed as 
geometric means for three independent repeats with lower and upper geo-metric 
standard error of the Mean values in parentheses (see Experimental for 
 
 
 
details).   
10 
 
 
 R1 R2 R3 n Ring IC50 (µM) Calc. LogPb 
10a H F H 0 Ph 2.24 (1.93, 2.59) 3.77 
10b 4-F F H 0 Ph 7.41 (6.25, 8.77) 3.93 
10c 4-OMe F H 0 Ph 13.7 (12.1, 15.5) 3.82 
10d 3-F H H 0 Ph 8.05 (7.67, 8.44) 4.74 
10e 4-F Me 4-OMe 0 Ph ≫50 
(16.7, 102) 
5.25 
10f 4-F Me 3-F 0 Ph 41.5 5.33 
10g 4-F Me 3-Me 0 Ph 4.00 (3.35, 4.78) 5.61 
10h 4-F Me 3-OMe 0 Ph 5.77 (5.08, 6.55) 5.22 
10i 4-F OMe H 0 Ph 1.80 (1.52, 2.14) 4.80 
10j 4-F F 4-F 0 Ph 1.52 (1.40, 1.66) 4.09 
10k 4-F F 3-F 0 Ph 4.47 (3.67, 5.45) 4.07 
10l 4-F H 3-F 0 Ph 6.31 (5.81, 6.84) 4.88 
10m 4-F F 2-F 0 Ph ≫50 
(6.74, 8.46) 
4.05 
10n 4-F F 3,4 di-F 0 Ph 7.55 5.00 
10o 4-F F 3-OMe 0 Ph No activity
a 
3.96 
10p 4-F F H 0 cHex 17.5 (13.1, 23.5) 4.14 
10q 4-F F H 1 Ph ≫50  3.63   
a No activity means < 5% inhibition observed at highest concentration of 
compound [50 µM in 3.0% (v/v) DMSO].
  
b LogP values calculated using http://www.molinspiration.com/cgi-bin/ 
properties. 
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Table 2  
IC50 values for the series of pyrazolopyrimidine inhibitors 11a–11k as mea-sured 
by the colorimetric assay [28] and calculated lipophilicity. IC50 values are 
expressed as geometric means for three independent repeats with lower and 
upper geometric standard error of the Mean values in parentheses (see Ex- 
 
 
perimental for details).  11 
 
 
 R1 R2 n IC50 (µM) Calc. LogPb 
11a 2-MeO N-(CH2)2CH3 0 No activity
a 
3.96 
11b 2-MeO N-(furan-2-carbonyl) 1 No activity
a 
2.62 
11c 2-MeO N-CH2CH3 1 ≫50 2.70 
11d 2-MeO N-(CH2)2CH3 1 7.35 (5.49, 9.83) 3.96 
11e 4-MeO N-(CH2)2CH3 1 No activity
a 
3.25 
11f 2,5-(MeO)2 N-(CH2)2CH3 1 No activity
a 
3.24 
11g 3-Me N-(CH2)2CH3 1 No activity
a 
3.62 
11h 2-Cl N-(CH2)2CH3 1 No activity
a 
3.83 
11i 2-MeO N-(CH2)2OH 1 No activity
a 
1.69 
11j 2-MeO O 1 No activity
a 
2.28 
11k 2-MeO CH-(piperidin-1-yl) 1 4.44 (3.66, 5.38) 3.76   
a No activity means < 5% inhibition observed at highest concentration of 
compound [50 µM in 3.0% (v/v) DMSO].
  
b LogP values calculated using http://www.molinspiration.com/cgi-bin/ 
properties. 
 
pyrazolopyrimidines 11a-11k (Table 2) were selected for further in-
vestigation. 
 
2.2. Characterization of inhibitor properties 
 
Initially, the enzymatic activity was assayed with 50 µM 10a-10q 
and 11a-11k in the presence of 3.0% (v/v) DMSO. The upper con-
centration in the pyrazoloquinoline series 10a-10q was limited to 50 
µM by solubility, as significant precipitation was observed at higher 
concentrations. Many compounds in the pyrazoloquinoline series 10a-
10q (Table 1) showed inhibition. On the other hand, most compounds 
in the pyrazolopyrimidine series 11a – 11k (Table 2) were inactive, 
with only two compounds (11d and 11k) displaying significant in-
hibitory activity.  
Active compounds were subsequently analysed using dose-response 
curves, in the presence of 3.0% DMSO, in order to determine their IC50 
values (Tables 1 and 2). The most potent compounds (10a, 10i and 10j) 
had IC50 values in the 1.5–2.3 µM range, which are similar values to those 
reported for some rationally designed inhibitors [28–32,37]. Analysis of the 
structure-activity relationships showed several inter-esting features. The 
phenyl ring bearing R1 was generally not very tolerant of substitutions at 
the 3- or 4-positions. Introduction of a small substituent (F) at the 4-position 
resulted in a ca. 3-fold increase in the IC50 (compound 10b vs. 10a), whilst 
introduction of a bulky OMe group (compound 10c vs. 10a) resulted in even 
more diminuation of in-hibitory activity. It is not clear if this phenomenon is 
a result of the steric or electron-withdrawing effect upon introduction of the 
fluorine. Fluorine has a relatively small van der Waals radius (ca. 1.35 Å), 
tra-ditionally viewed as similar to hydrogen (1.10 Å) [43,44]. Similarly, 
carbon-fluorine bonds (1.26–1.47 Å) are traditionally viewed as isos-teric 
with carbon-hydrogen bonds (1.08–1.2 Å) [43,45], but some stu-dies have 
suggested that carbon-fluorine bonds are more similar to carbon-oxygen 
bonds (1.52 Å) [44,45]. The high electronegativity of fluorine [43–45] and 
the increased lipophilicity of fluorine-containing compounds [43] have been 
extensively exploited in drug design. The compounds selected did not allow 
for direct evaluation of the effect of introducing a 3-F group but the results 
suggest that this substitution is also not particularly well tolerated 
(compounds 10d, 10l and 10n). This 
 
 
behaviour appears to primarily result from steric effects [43–45]. In 
contrast, substitutions at R2 appear to be well tolerated. Matching of 
compounds suggests that R2 = H, F or, Me or OMe has little effect on 
the observed IC50. However, there are unexplained exceptions to this 
general rule, e.g. 10h (R2 = Me) has an IC50 = 5.77 µM, whilst 10o 
(which differs only in R2 = F) is inactive (Table 1).  
Substitution of the amide phenyl group (R3) showed several inter-esting 
trends. Small groups, e.g. F, at the 4-position were well tolerated and 
appeared to increase potency (10j vs. 10b). In contrast, addition of a larger 
group (OMe; 10e), almost abolished inhibitory activity, al-though, in this 
case, the analysis is complicated by the simultaneous change of R2 from F 
to Me. When R3 = 3-F this resulted in a ~3-fold decrease in activity 
(compounds 10k, 10l, and 10n). The presence of the larger group (OMe) 
had an inconsistent effect, as noted above, with 10h having a similar 
activity to 10l, whilst 10o lost all activity. Finally, introduction of a 2-F group 
as R3 almost abolished activity (compound 10m vs. 10j). Analysis of the 
side-chain amide moiety showed that substituting the phenyl ring with 
cyclohexyl- (compound 10p vs. 10b) decreased activity (IC50 = 17.5 vs. 
7.41 µM). Extending the side-chain with a methylene group (compound 10q 
vs. 10b; n = 1 vs. n = 0) re-sulted in almost complete loss of inhibitory 
activity (Table 1).  
All of these compounds displayed reversible inhibition, as judged 
by rapid dilution experiments (Supporting Information). However, it 
was notable that most dose-response curves had Hill coefficients 
which were significantly higher than 1 with a few compounds having an 
average Hill coefficient of > 3 (10b, 10d, 10g, 10h and 10i) indicating 
that these compounds were not well-behaved inhibitors. We 
considered the possibility that inhibition of AMACR arose due to 
aggregation of com-pounds or other Pan-Assay Interference 
mechanisms [41,42]. Control experiments showed that inhibition was 
retained when assays were conducted in the presence of Triton X-100 
(Supporting Information, Fig. S2), implying that compound aggregation 
was not a significant factor. Moreover, compounds were negative 
when analysed for Pan-Assay Interference properties [42]. We also 
considered whether the observed high H-coefficients arose due to 
problems with inhibitor so-lubility, and hence investigated whether 
pIC50 values or Hill coefficients were correlated with LogP values but 
no trends were apparent (Supporting Information, Figs. S3 and S4). 
Kinetic analysis of inhibition by 10a and 10j (Supporting Information) 
was used to determine the type of inhibition. In the case of 10a 
uncompetitive inhibition was observed, with a Ki value of 4.8 ± 0.7 µM 
(mean ± S.E.M.) (vide infra). In contrast, mixed competitive inhibition 
was observed for 10j, with a Ki value of 2.4 ± 0.9 µM (mean ± S.E.M.), 
with α = 6.6. This latter behaviour is consistent with model in which the 
inhibitor binds to the adenosine site of the coenzyme A moiety.  
In the case of the pyrazolopyrimidine series of compounds (11a-  
11k), only two examples (11d and 11k) showed inhibition at 50 µM. It 
is striking that the inactive nine compounds had only minor structural 
differences compared to the active compounds (Table 2). Further ki-
netic analysis of inhibition 11k in the presence of 3.0% (v/v) DMSO 
showed that it was an uncompetitive inhibitor, with a Ki value of 4.6 ± 
0.4 µM (mean ± S.E.M.). This type of inhibition arises from exclusive 
binding of the inhibitor to the enzyme-substrate complex, with no 
significant binding to enzyme alone [46]. This behaviour is inconsistent 
with a mode of action in which the inhibitor binds to the site occupied 
by the adenosine moiety of the CoA because the inhibitor binds only to 
the enzyme-substrate complex. The crystal structures of MCR [11–13] 
show that the enzyme is a dimer, with basic side-chains in the active 
site catalysing deprotonation and reprotonation contributed by both 
subunits. Theoretically, uncompetitive inhibition could occur by 10a or 
11k binding to one active site whilst the other is occupied by substrate. 
However, this requires that substrate binding to subunits is cooperative 
and there is no evidence that this is the case (Hill coeffi-cient is ~1 
when kinetic data is fitted to the cooperative model). The mode of 
action is therefore unclear at this time but it could be that the inhibitor 
binds between the two dimer subunits and this may explain 
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why many analogues of 11k are inactive (Table 2). 
 
3. Conclusions 
 
The new colorimetric assay [28,37] allows rapid identification of 
inhibitors by high-throughput screening. The assay is simple to use, 
consisting of mixing of the enzyme and drug stock solutions followed 
by addition of substrate stock solution after the desired pre-incubation 
period. Monitoring formation of product over time allows convenient 
characterization of inhibitory properties, including IC50 and Ki values, 
and determining whether the inhibitor is reversible or not. For optimum 
sensitivity, a kinetic assay is used, although the assay is sufficiently 
sensitive to use an end-point format. A disadvantage of the end-point 
format is that many potential inhibitors absorb at 354 nm and this 
complicates analysis of the results. Our reported assay contrasts with 
the radiochemical assay used for high-throughput screening of 
AMACR reported by Wilson et al. in 2011 [22], which required multiple 
steps and physical separation of the products using column 
chromatography. Our study also differs in that the discovered inhibitors 
are not non-specific protein-modifying agents, in contrast to the 
compounds re-ported by Wilson et al. [22].  
This study identifies pyrazoloquinolines and pyrazolopyrimidines as 
new classes of AMACR inhibitor. The libraries of drug-like compounds 
used in this screening study were provided by LifeArc [40]. Similar 
compounds to those identified in this study have been reported as in-
hibitors of various kinases [47–53] and also of bacterial cell-wall bio-
synthetic enzymes which use UDP derivatives as substrates [54]. 
However, this appears to be the first report of such compounds in-
hibiting an enzyme using an acyl-CoA substrate. Kinetic analysis of 
pyrazoloquinoline inhibitor 10j showed that it was mixed competitive, 
consistent with it binding to the same site as the adenosine moiety of 
the CoA as well as to the enzyme substrate complex. In contrast, the 
pyrazoloquinoline inhibitor 10a and the pyrazolopyrimidine inhibitor 
11k were uncompetitive. These appear to be the first examples of un-
competitive AMACR inhibitors, while all other characterized reversible 
inhibitors been competitive [28]. Uncompetitive inhibition offers sig-
nificant advantages over other types of inhibition for pharmacological 
applications in that inhibition is increased at high substrate con-
centrations compared to low substrate concentrations [46]. This means 
that inhibition of the enzyme within the cell is not eventually overcome 
by the build-up of substrate and precursors. The results of this paper 
demonstrate that our high-throughput screening assay is suitable for 
identifying novel, ‘druggable’ compounds as AMACR inhibitors. 
 
4. Materials and methods 
 
4.1. Sources of materials 
 
Chemicals were purchased from the Sigma-Aldrich Chemical Co. 
or Fisher Scientific Ltd., unless otherwise stated, and were used 
without further purification. Reduced coenzyme A, tri-lithium salt, was 
pur-chased from Calbiochem. High-throughput screening libraries 
were obtained as 1.0 mM solutions in DMSO from LifeArc in 384-well 
plates [40]. Human recombinant AMACR 1A was expressed and 
purified and substrate 7 was synthesized as previously described [28]. 
Inhibitors 10 and 11 were obtained from Chemdiv; 1H NMR and mass 
spectrometric data for these compounds (Supporting Information) were 
supplied by Chemdiv. 
 
4.2. High-throughput screening 
 
A protocol modified from that previously reported assay based on 
elimination of 2,4-dinitrophenolate 8 [28,37] was used to screen the 
libraries. A multi-channel pipette was used to add 6.0 µL of stock so-lution 
of inhibitor in DMSO into a 96 well plate, followed by 294 µL of enzyme 
stock solution in 50 mM aq. NaH2PO4-NaOH, pH 7.4. Following 
 
 
10 min incubation at ambient temperature, the mixture was divided into 
3 × 100 µL and the enzymatic reaction was initiated by adding 2 × 
substrate stock solution (3 × 100 µL) in the same buffer with the plate 
incubated at 30 °C. Final concentrations in the assay of potential 
inhibitor, DMSO, substrate 7 and enzyme were 30 µM, 3.0% (v/v), 40 
µM, and ~0.04 mg.mL−1, respectively. Formation of product was 
followed at 354 nm (and 390 nm) for 8 min, using a BMG Labtech 
FLUOstar Omega plate reader with Omega software. Potential hits 
were rescreened under the same conditions and compared to positive 
(en-zyme + DMSO) and negative controls (buffer + DMSO). Under 
these conditions, Z′ = 0.71 ± 0.13 (mean ± standard deviation, three in-
dependent repeats) for measurement at 354 nm. Some assays were 
conducted in 96 well half-volume plates, in a final volume of 100 µL 
with the same reagent concentrations. Control assays show identical 
results with both types of plate [28]. 
 
4.3. Evaluation of AMACR inhibition 
 
Colorimetric assays were performed as previously described 
[28,37]. Assays were typically conducted in half-volume 96-well plates, 
in a final volume of 100 µL. Each assay mixed 9.0 µL DMSO stock and 
141 µL enzyme stock. After 10 min, this was divided into 3 × 50 µL and 
the assay was initiated by addition of 3 × 50 µL of colorimetric sub-
strate 7 in buffer. The following final concentrations were used in dose-
response curves: inhibitors, 50, 16.7, 5.55, 1.85, 0.617, 0.205, 0.068 
and 0.022 µM; DMSO, 3% (v/v); substrate, 40 µM; and enzyme, 
0.0396 mg mL−1. Reaction rates were determined by plotting A354 with 
time in Excel [28] and data were analysed using SigmaPlot 13. Log10 
IC50 values were calculated from individual dose-response curves with 
inhibition of binding plotted against Log10 drug concentration (in M). 
Mean Log10 IC50 values were then calculated from 3 repeats together 
with corresponding Log10 Standard Error of the Mean (S.E.M.) values. 
Data were then converted to non-logarithmic values to produce the 
geometric mean with corresponding upper and lower limits of the 
geometric S.E.M. values (in µM); see Tables 1 and 2. Compounds 
were screened for Pan-Activity Inhibition using the following websites: 
https://www.cbligand.org/PAINS/ [42] and http://zinc15.docking. 
org/patterns/home/.  
Reversibility experiments (See Supporting Information) used in-
hibitor at ca. 10 × IC50 value in experiment 1, with all other reagents at 
the above concentrations and a 100 µL final volume. Experiment 2 
used concentrated enzyme (1.69 mg mL−1) which was incubated with 
in-hibitor and DMSO at the same concentrations as in Experiment 1. 
After 10 min, the mixture was diluted with 6.0% (v/v) DMSO to give the 
same enzyme concentration as in Experiment 1 and 3 × 50 µL was 
placed in the plate. Substrate stock solution (3 × 50 µL) was added to 
the diluted enzyme/drug mixture and the reaction was followed at 354 
nm for 15.5 min. Average A354 values and standard deviations (n = 3) 
were calculated in Excel [28]. Positive controls contained en-zyme + 
DMSO and negative controls contained buffer + DMSO.  
The Ki value for 10a was determined at a fixed concentration of 0, 1.43, 
2.31 and 3.71 µM in the assay. For 10j a fixed concentration of 0, 
0.87, 1.52 and 2.65 µM were used. Rates were determined at 354 nm for 
eight concentrations of substrate (100, 66.6, 44.4, 29.6, 19.7, 13.2, 8.7 and 
5.85 µM final concentration in assay); in the case of 10a and 10j significant 
substrate inhibition was observed at higher substrate con-centrations. 
Therefore, the 5 or 6 of the lowest substrate concentrations were used in 
this analysis. DMSO and enzyme concentrations were 3.0% (v/v), and 
0.0396 mg mL−1, respectively. The Ki value for 11k was determined using 
a fixed concentration of 0, 1.24, 4.44 and 15.88 µM. The same substrate, 
DMSO and enzyme concentration was used as above. Rates were 
determined in Excel, as above, and kinetic parameters determined using 
SigmaPlot 13 with the exploratory EK and enzyme kinetics modules. 
Inhibitory mode was decided by visual in-spection of plots and ranking of 
solutions by SigmaPlot 13. 
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